Loading...
Loading...
LEGN| Name | Value |
|---|---|
| Revenues | 79.5M |
| Cost of Revenue | 37.8M |
| Gross Profit | 41.7M |
| Operating Expense | 162.7M |
| Operating I/L | -121.1M |
| Other Income/Expense | -25.8M |
| Interest Income | 17.3M |
| Pretax | -146.8M |
| Income Tax Expense | -2.0M |
| Net Income/Loss | -144.8M |
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cell therapies for oncology and other indications. Its lead product candidate, LCAR-B38M, is a chimeric antigen receptor for the treatment of multiple myeloma, with additional product candidates targeting various cancers and infectious diseases. The company generates revenue through the development and commercialization of its cell therapy products, including collaborations and license agreements with partners such as Janssen Biotech, Inc. for the advancement of specific therapies.
